fda mrna vaccine - Search News

Order byBest matchMost fresh

FDA, COVID and vaccines

FDA expands COVID vaccine warning about possible side effect

The FDA is requiring COVID vaccine makers Pfizer and Moderna to update their warnings about the possible risk of myocarditis and pericarditis.

· 1d · on MSN

FDA requires Covid vaccine makers to expand warning about risk of rare heart inflammation

· 22h

FDA Warns of Heart Risk With Pfizer, Moderna COVID Vaccines

FDA panel recommends keeping COVID shots targeted to same strain as last year

Advisers to the Food and Drug Administration have recommended COVID-19 vaccine makers continue to target their shots to the so-called JN.1 coronavirus strain for the upcoming fall and winter seasons, ...

· 18h

· 1d

FDA limits access to COVID-19 vaccine to older adults and other high-risk groups – a public health expert explains the new rules

wtvr · 16h

FDA advisory committee meets on COVID-19 vaccine after putting new restrictions on approvals

US FDA Advisers to Weigh Composition of COVID Vaccines for 2025-2026

Public health experts say that there is no certainty on which strains are going to be dominant.

· 22h

· 1d

FDA plans to limit COVID vaccine to only high-risk people. Who would still be eligible?

· 23h

FDA panel debates COVID vaccine recipe as questions swirl about fall shots

STAT17h

FDA asks mRNA vaccine makers to widen age range for rare heart risk warning

In another sign of growing scrutiny over Covid-19 vaccines, the Food and Drug Administration has asked the two makers of mRNA vaccines to widen the age range of boys and young men that their labels say are at risk for a rare side effect causing heart inflammation.

What we know about the safety, efficacy of mRNA vaccines amid recent scrutiny

Infectious disease experts say mRNA vaccines have been studied for decades, they are safe and effective, and were instrumental in saving lives during the COVID pandemic.

Zacks Investment Research on MSN22h

MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot

Shares of Moderna MRNA declined nearly 8% yesterday after it announced that it had voluntarily withdrawn a regulatory filing seeking the FDA’s approval for mRNA-1083, its investigational mRNA-based combination vaccine against influenza and COVID.